Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection

Overview

Human papillomavirus (HPV) infection is a worldwide problem strictly linked to the development of cervical cancer. Persistence of the infection is one of the main factors responsible for the invasive progression and women diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection. In this study the investigators will evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based local treatment in improve the viral clearance reducing the time exposure to the infection and avoiding the complications associated with the invasive treatments currently available. Women diagnosed with HPV infection were randomly assigned to receive six months of treatment with a PHMB-based gynaecological solution (Monogin®) or to remain untreated for the same period of time. The administration of Monogin® has been performed every three days for fifteen days and then every fifteen days for the subsequent six months.

Study Type

  • Study Type: Interventional

Interventions

  • Device: Monogin
    • Gynaecological solution with polyhexamethylene biguanide, pH 4.0

Arms, Groups and Cohorts

  • Experimental: Monogin
  • No Intervention: No intervention

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients with no HPV infection

Participating in This Clinical Trial

Inclusion Criteria

  • pathologic Pap smear – positive "high risk" HPV DNA test – positive colposcopy examination Exclusion Criteria:

  • patients who had undergone wart therapy in the previous six months – pregnancy – invasive disease – immunosuppression – previous HPV vaccination

Gender Eligibility: Female

Minimum Age: 30 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AGUNCO Obstetrics and Gynecology Centre
  • Provider of Information About this Clinical Study
    • Sponsor

References

Zanotti KM, Belinson J. Update on the diagnosis and treatment of human papillomavirus infection. Cleve Clin J Med. 2002 Dec;69(12):948, 951-5, 956 passim. doi: 10.3949/ccjm.69.12.948.

Hubner NO, Kramer A. Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic. Skin Pharmacol Physiol. 2010;23 Suppl:17-27. doi: 10.1159/000318264. Epub 2010 Sep 8.

Marelli G, Papaleo E, Origoni M, Caputo L, Ferrari A. Polyhexamethylene biguanide for treatment of external genital warts: a prospective, double-blind, randomized study. Eur Rev Med Pharmacol Sci. 2005 Nov-Dec;9(6):369-72.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.